Jump to content

Durata Therapeutics

From Wikipedia, the free encyclopedia
Durata Therapeutics, Inc.
IndustryPharmaceutical industry
Founded2009; 15 years ago (2009)
DefunctNovember 17, 2014; 9 years ago (November 17, 2014)
FateAcquired by Actavis (now Allergan)
HeadquartersMorristown, New Jersey

Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.

History

[edit]

On December 21, 2009, the company acquired Vicuron Pharmaceuticals and its drug candidate, dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer and commenced operations.[1]

On April 19, 2011, the company initiated Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.[2]

In 2012, the company moved its global headquarters from Morristown to Chicago and received $2 million in tax credits.[3]


References

[edit]
  1. ^ "Newly Formed Durata Therapeutics Acquires Pfizer's Vicuron Subsidiary" (Press release). PR Newswire. December 21, 2009.
  2. ^ "Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections" (Press release). Business Wire. April 19, 2011.
  3. ^ Frost, Peter (November 14, 2012). "Durata biotech moving headquarters to Chicago". Chicago Tribune.